Estimating regimen-specific costs of chemotherapy for breast cancer: Observational cohort study.

ABSTRACT:

Background

One goal for high-quality patient care is communicating treatment costs to patients, yet cost information can be elusive. This is especially relevant for breast cancer care, for which numerous guideline-concordant adjuvant chemotherapy regimens exist. The objective of the current study was to generate cost estimates for such regimens from payers' and patients' perspectives in a large, insured US population.

Methods

Adult women who had incident breast cancer diagnosed between 2008 and 2012 (from the MarketScan database), had no secondary malignancy within 1 year of diagnosis, and received chemotherapy within 3 months of diagnosis were included (n = 14,643). Total and out-of-pocket costs were calculated using all claims within 18 months of diagnosis and were normali

SUBMITTER: Giordano SH 

PROVIDER: S-EPMC5479741 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature